Search Results

You are looking at 1 - 10 of 19 items for :

  • "genetic risk assessment" x
Clear All
Full access

Mary B. Daly, Jennifer E. Axilbund, Saundra Buys, Beth Crawford, Carolyn D. Farrell, Susan Friedman, Judy E. Garber, Salil Goorha, Stephen B. Gruber, Heather Hampel, Virginia Kaklamani, Wendy Kohlmann, Allison Kurian, Jennifer Litton, P. Kelly Marcom, Robert Nussbaum, Kenneth Offit, Tuya Pal, Boris Pasche, Robert Pilarski, Gwen Reiser, Kristen Mahoney Shannon, Jeffrey R. Smith, Elizabeth Swisher and Jeffrey N. Weitzel

Assessment Cancer genetic risk assessment and genetic counseling is a multistep process of identifying and counseling individuals at risk for familial or hereditary cancer. Cancer genetic risk assessment involves use of pedigree analysis with available

Full access

Kaylene Ready and Banu Arun

become familiar with its process. Cancer Genetic Risk Assessment To better understand how to manage patients who have an increased risk of breast cancer based on family history, a basic understanding of the process of cancer genetic risk

Full access

Wylie Burke and Nancy Press

screening with MRI—what are the data for patients at high risk? N Engl J Med 2004 ; 351 : 497 – 500 . 11. Nelson HD Huffman LH Fu R Harris EL . Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility

Full access

Deborah Cragun, Anne Weidner, Ann Tezak, Brenda Zuniga, Georgia L. Wiesner and Tuya Pal

cancer genetic risk assessment and GC or testing for any type of cancer-related condition. Patients were seen by GHPs staffing the clinic, including 2 board-certified clinical geneticists, 2 board-certified genetic counselors, and 1 nurse practitioner

Full access

Tarra Evans and Ursula Matulonis

Clinical Implications Genetic Risk Assessment During the past decade, NGS panels of genes associated with gynecologic malignancies have become important tools in counseling patients and families concerning cancer risk, risk-reduction planning, and

Full access

NCCN Guidelines Insights: Survivorship, Version 2.2020

Featured Updates to the NCCN Guidelines

Crystal S. Denlinger, Tara Sanft, Javid J. Moslehi, Linda Overholser, Saro Armenian, K. Scott Baker, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Norah Lynn Henry, Christine Hill-Kayser, Melissa Hudson, Nazanin Khakpour, Divya Koura, Allison L. McDonough, Michelle Melisko, Kathi Mooney, Halle C. F. Moore, Natalie Moryl, Tracey O’Connor, Electra D. Paskett, Chirayu Patel, Lindsay Peterson, William Pirl, M. Alma Rodriguez, Kathryn J. Ruddy, Lillie Shockney, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Phyllis Zee, Nicole R. McMillian and Deborah A. Freedman-Cass

previously did not meet criteria for genetic risk assessment may now qualify for genetic testing. Thus, the panel concluded that periodic review of family cancer history in cancer survivors is important to reassess the risk of a hereditary cancer syndrome

Full access

Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Simon Kim, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Kelvin A. Moses, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J. Vickers, Robert Wake, Dorothy A. Shead and Deborah A. Freedman-Cass

gene. 64 – 68 The panel received an external submission requesting that genetic risk assessment be recommended in the NCCN Guidelines for Prostate Cancer Early Detection based on recommendations in the NCCN Guidelines for Genetic/Familial High

Full access

Brandie Heald, Shanna Gustafson, Jessica Mester, Patricia Arscott, Katherine Lynch, Jessica Moline and Charis Eng

8000 patients at these centers would need to undergo a genetic risk assessment and, potentially, genetic testing in the setting of genetic counseling. Using the data from this study, a GCO model would be 30% more efficient than a GC/MD seeing this

Full access

Michael J. Hall

. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization . J Gen Intern Med 2009 ; 24 : 822 – 828 . 26. Lerman C Hughes C Croyle RT . Prophylactic surgery decisions and surveillance

Full access

affecting optimal cancer management. Updated Genetic Screening Guidelines Published by NCCN Feature Emerging Evidence on Personalized Medicine NCCN recently announced the publication of the newest genetic risk assessment recommendations for breast, ovarian